CompanyALNYNasdaqCambridge, MA

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals develops RNAi therapeutics using siRNA to silence disease-causing mRNAs.

SEC EDGAR ClinicalTrials.gov alnylam.com

424B4Sep 28Latest SEC filing

Jul 30Latest story

July 2026

Alnylam cuts 2026 TTR revenue outlook, advances Alzheimer's and rare disease pipeline

Jul 30Quarterly updateAlnylam Pharmaceuticals